``Whatever statistical study you use, you find that rosiglitazone still increases the risks of heart attack and heart failure,'' said Yoon Loke, a clinical pharmacologist at the University of East Anglia in Norwich, England, and a co-author of another Avandia study in JAMA ``If you get the same results with different methods, this implies the finding is quite robust.''
Meanwhile......
In the same journal comes some possible good news for Takeda's glitazone, Actos.
Hmmm. Lets see!
Time to break out the stress balls, perhaps?
No comments:
Post a Comment